DISCOVER
eISF
THE ELECTRONIC INVESTIGATOR SITE FILE
The eISF, or electronic Investigator Site File, is the digital version of the paper-based investigator site file (ISF). It enables the collection in digital form of essential documents that demonstrate a clinical trial was conducted in accordance with Good Clinical Practice (GCP) guidelines, as well as regulatory and sponsor requirements. These documents include the protocol, informed consent forms, study reports, lab results, and other documentation related to the trial.
Leads to this page
The eISF is stored in a secure, web-based system that is accessible to authorized personnel only
The use of eISFs has several advantages over paper-based ISFs :
• efficiency in document management
• increases accuracy and completeness of data
• enhances security of sensitive information
• facilitates remote monitoring of study sites
• real-time data access and sharing between sites, sponsors, and regulatory agencies
Theuse of eISFs represents a significant step forward in the conduct of clinical research, enabling faster and more efficient trial management while ensuring compliance with regulatory and ethical standards.
LATEST NEWSOUR NEWS >
December 13, 2025
Mind Health With 53,000 new cases diagnosed each year, lung cancer is the deadliest cancer in France, according to data from the National Cancer Institute. Three-quarters of cases are detected at an advanced stage, which reduces the chances of recovery. The importance of screening is therefore crucial. In this field, the combination of low-dose CT […]
November 27, 2025
Med City News Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost […]
November 27, 2025
Trial Site News Clinical trial reporting of treatment efficacy is the foundation of public trust in medicine. Yet pharmaceutical companies often report efficacy measured as a relative risk reduction (RRR) while omitting the more relevant absolute risk reduction (ARR). This statistical sleight of hand can make clinically insignificant benefits look spectacular! Consider a simple example A risk is […]